UNLOXCYT is the initial FDA-approved therapy for advanced cutaneous squamous cell carcinoma as announced by Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics has received FDA approval for UNLOXCYT (cosibelimab-ipdl). Read More »
NEW YORK, June 03, 2024 – Rosen Law Firm, a worldwide investor rights law firm, is reminding individuals who bought securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March…
Law Offices of Howard G. Smith is reminding investors that class action lawsuits have been filed on behalf of shareholders of certain companies.
The Law Offices of Frank R. Cruz is reminding investors that class action lawsuits have been filed on behalf of shareholders.
The Law Offices of Frank R. Cruz is reminding investors about class action lawsuits filed on behalf of shareholders of specific companies.
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a well-known firm specializing in protecting the rights of stockholders, is notifying investors about a class action lawsuit that has been initiated against…
Faruqi & Faruqi, LLP, a prominent national securities law firm, is looking into potential claims against Checkpoint Therapeutics, Inc. (Checkpoint or the…)
Faruqi & Faruqi, LLP is investigating claims on behalf of investors of Checkpoint. Read More »
The Rosen Law Firm, an international law firm focusing on investor rights, is reminding individuals who bought securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March…
Faruqi & Faruqi, LLP, a prominent national securities law firm, is looking into possible claims against Checkpoint Therapeutics, Inc. (Checkpoint or the…)
Bragar Eagel & Squire, P.C., a well-known law firm specializing in shareholder rights, is reminding investors that class actions have been initiated on their behalf.
Stay updated with the latests analysis and insights fromm etfsector.com